1lambda~6~-Thiocane-1,1-dione | 3142-87-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: 1lambda~6~-Thiocane-1,1-dione
• 英文别名: thiocane 1,1-dioxide
• CAS: 3142-87-8
• 化学式: C₇H₁₄O₂S
• 分子量: 162.25
• InChiKey: WWDVSDDDSOGBOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Indazole-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1479675A1

  公开（公告）日：2004-11-24

  The present invention relates to compounds of the formulae I and Ib wherein R0 ; R1 ; R2 ;Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ib, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I和Ib的化合物 其中R0; R1; R2; Q; V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝块酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于因子Xa和/或因子VIIa的不良活性存在或因子Xa和/或因子VIIa的抑制而打算治愈或预防的情况。此外，本发明还涉及制备式I和Ib的化合物的方法，它们的用途，特别是作为药物中的活性成分，并包括它们的制药制剂。
• Benzimidazole-derivatives as factor xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1479676A1

  公开（公告）日：2004-11-24

  Benzimidazole-derivatives as factor Xa inhibitors The present invention relates to compounds of the formula I, wherein R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  苯并咪唑衍生物作为因子Xa抑制剂本发明涉及以下式I的化合物，其中R0; R1; R2; R3; R4; Q; V，G和M具有所述声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa不良活性的情况，或者用于治疗或预防需要抑制因子Xa和/或因子VIIa的情况。此外，本发明还涉及式I化合物的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制剂。
• RADIATION-SENSITIVE RESIN COMPOSITION, RESIST PATTERN-FORMING METHOD, AND COMPOUND
  申请人：JSR CORPORATION

  公开号：US20180319740A1

  公开（公告）日：2018-11-08

  A radiation-sensitive resin composition includes a first polymer including a first structural unit that includes a first acid-labile group; a radiation-sensitive acid generator; and a compound represented by formula (1). n is 1 or 2. R 1 represents a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms in a case in which n is 1. R 1 represents a divalent organic group having 1 to 20 carbon atoms in a case in which n is 2. R 2 represents a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. E represents a group represented by formula (i). R 2 and E may taken together represent a ring structure having 3 to 20 ring atoms together with the nitrogen atom. X represents a divalent organic group having 1 to 20 carbon atoms. R 3 represents a second acid-labile group.

  一种辐射敏感性树脂组合物包括第一聚合物，其中包括第一个酸敏感基团的第一个结构单元；辐射敏感性酸发生剂；以及由式（1）表示的化合物。n为1或2。当n为1时，R1代表氢原子或具有1至20个碳原子的一价有机基团。当n为2时，R1代表具有1至20个碳原子的二价有机基团。R2代表氢原子或具有1至20个碳原子的一价有机基团。E代表由式（i）表示的基团。R2和E可能一起表示具有3至20个环原子的环结构，与氮原子一起。X代表具有1至20个碳原子的二价有机基团。R3代表第二个酸敏感基团。
• Azaindole derivatives as Factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1479680A1

  公开（公告）日：2004-11-24

  The present invention relates to compounds of the formula I wherein R0 ; R1 ; R2 ;Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及具有式I的化合物，其中R0；R1；R2；Q；V，G和M具有所述声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可应用于存在因子Xa和/或因子VIIa的不良活性或需要抑制因子Xa和/或因子VIIa的治疗或预防条件。此外，该发明涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，并包括它们的药物制剂。
• Nociceptin analogs
  申请人：——

  公开号：US20030013874A1

  公开（公告）日：2003-01-16

  A compound of the having the general formula (I) or general formula (II): 1 wherein Z, A, B, C, R 1 , R 2 , Q, W, and n are as described herein.

  一个化合物，其一般化学式为（I）或一般化学式为（II）：其中Z、A、B、C、R1、R2、Q、W和n如本文所述。